The Liver Meeting 2024 - Debrief Sessions - Spanish-Choleostasis Debrief Session

Video Transcription

Video Summary

Dr. Aparna Goel from Stanford University discussed recent advancements in cholestatic liver disease at a conference on gastroenterology and hepatology. Her presentation covered new treatments for primary biliary cholangitis (PBC) such as alofibrinol and saladelpar, highlighting the need for dynamic management due to high discontinuation rates of existing therapies. Dr. Goel also addressed the efficacy and safety of pharmaceutical treatments like fibrates, obeticholic acid, and novel agents like celadelpar in treating various liver diseases. Additionally, she emphasized the significance of managing symptoms such as pruritus and liver fibrosis for improving patients' quality of life. Biomarkers and surrogate endpoints remain critical in evaluating treatment efficacy, particularly in diseases like primary sclerosing cholangitis (PSC). Novel drugs like Bexotograst and CM101 show promise in treating PSC, while anti-TNF therapies provide new avenues in autoimmune hepatitis research. Overall, these advancements underscore an exciting period for research and treatment in cholestatic liver diseases.

Keywords

cholestatic liver disease

primary biliary cholangitis

treatment advancements

biomarkers

primary sclerosing cholangitis

autoimmune hepatitis